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ABSTRACT 
Objective: Thyroid dysfunction was found to be more common among women with metabolic syndrome. A cross-sectional analysis showed that 
subjects with subclinical hypothyroidism (SH) had high prevalence of cardiovascular disease than euthyroid subjects. The objective of the current 
study is to evaluate the prevalence of metabolic syndrome and cardiovascular risk factors among subclinical  hypothyroid subjects.  
Methods:  Thirty untreated subclinical hypothyroid women and thirty normal healthy subjects were recruited for the study. Fas ting blood samples 
were collected for lipid profile, glucose and insulin level estimation. 
 Results: Fasting plasma glucose, total cholesterol, triglycerides and LDL-cholesterol were found to be significantly increased in SH patients Both 
systolic and diastolic blood pressures were higher in the patient group. 43.3% of the SH patients were found to satisfy the criteria for metabolic 
syndrome.  
Conclusion: In our study, subclinical hypothyroidism is significantly associated with metabolic syndrome and its components. Whether this 
association might be translated into a compounded cardiovascular risk needs to be evaluated by further studies. 
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INTRODUCTION 
Subclinical hypothyroidism is defined as an asymptomatic condition 
with high serum TSH levels and normal free thyroid hormone levels 
[1]. The rate of progression to frank hypothyroidism has been 
shown to be 2-5% per year being more prevalent in women and 
elderly people [2]. Metabolic syndrome is a cluster of risk factors 
characterized by hypertension, atherogenic dyslipidemia, 
hyperglycemia, prothrombotic and proinflammatory conditions [3]. 
Thyroid function affects the parameters causing metabolic 
syndrome including low density lipoproteins, triglycerides, blood 
pressure and plasma glucose. A higher prevalence of thyroid 
disorders is reported in type 2 diabetes mellitus [4]. 
The prevalence of thyroid dysfunction was reportedly more among 
women with metabolic syndrome [5, 6].  The prevalence of 
cardiovascular disease is 2-3 times higher in individuals with 
metabolic syndrome [7]. A cross-sectional analysis revealed that 
subjects with subclinical hypothyroidism had a significantly higher 
prevalence of cardiovascular disease than euthyroid subjects [8].  
There is increasing evidence that both metabolic syndrome and 
subclinical hypothyroidism are associated with an increased 
cardiovascular risk. Data regarding the relationship between 
metabolic syndrome and thyroid function is conflicting. Hence, we 
undertook this study to examine the prevalence of metabolic 
syndrome among subclinical hypothyroid subjects and also to assess 
the traditional cardiovascular risk factors in these patients.  
MATERIALS AND METHODS 
Based on their thyroid profile, thirty untreated subclinical 
hypothyroid subjects and thirty age matched healthy women in the 
20-60 years were recruited for the study from SRM Medical College 
Hospital and Research Centre. Cases with history of overt 
hypothyroidism, renal disease, cardiac disease, acute infection and 
liver disease were excluded from the study. The Institutional ethical 
committee approved the study and a written informed consent was 
obtained from the subjects. 
Fasting blood samples were collected. The samples were 
centrifuged, separated and analyzed using Beckman Coulter 
autoanalyzer AU400 on the same day of collection. Serum levels of 
total cholesterol, HDL-C, triglycerides and plasma glucose were 
measured using enzymatic methods with reagents supplied by 
Beckman Coulter Inc., USA. Thyroid profile assay for selection of 
subjects was done by competitive enzyme immunoassay (Automated 
Immunoassay analyzer -360) from TOSOH Corporation, Japan. 
Metabolic syndrome was diagnosed when three or more of the 
following were present: Waist circumference more than 35 inch 
(women), Blood pressure > 130/85 mm Hg, plasma glucose > 100 
mg/dL, triglycerides > 150 mg/dL, HDL-C < 50 mg/dL. 
Statistical analysis was performed using SPSS software version 17. 
Student's t-test, chi-square test were used for comparison of 
qualitative data. Pearson correlation was used for the analysis of p 
value and correlation for scale variable. p value < 0.05 is considered 
significant. Data were defined as mean ± SD. 
RESULTS 
Clinical and biochemical characteristics of the study groups are 
given in Table  1. Systolic and diastolic blood pressures in subclinical 
hypothyroidism patients were significantly higher than values in 
controls. The two groups did not differ in waist circumference, HDL-
cholesterol, insulin levels and HOMA-IR.  Fasting plasma glucose, 
total cholesterol, triglycerides and LDL-cholesterol levels were 
significantly higher in SH group than in controls. 
Table 1. Clinical and biochemical characteristics of the subclinical hypothyroid and control groups 
Variables Subclinical hypothyroidism group Control group P value 
Age 37.35±10.26 34.55±9.34 NS 
BMI 25.1±4.56 24±3.2 NS 
Serum TSH (µIU/mL) 7.51±1.21 2.23±0.32 <0.01 
Serum FT3 (pg/mL) 2.72±0.58 2.43±0.44 NS 
Serum FT4 (ng/dL) 0.92±0.14 0.82±0.12 NS 
 Vol 6, Issue 4, 2013                                                                                                                                                                                                   ISSN - 0974-2441                                                                                                                                                                                                 
Pangaluri et al. 
Asian J Pharm Clin Res, Vol 6 Issue 4, 2013, 82-84 
83 
 
Waist circumference (cm) 82.8±12.4 81.5±10.2 NS 
Systolic blood pressure (mm Hg) 127.6±15.8 108.3±9.12 <0.01 
Diastolic blood pressure (mm Hg) 81.6±11.16 73.3±6.6 <0.01 
Total cholesterol (mg/dL) 172.4±23.9 155.6±21.4 0.002 
Triglycerides (mg/dL) 140.5±44.8 94.8±25.2 <0.001 
LDL-C (mg/dL) 106.4±21.23 95.2±21.4 <0.05 
HDL-C (mg/dL) 43.7±10.3 42.0±8.8 NS 
Fasting glucose (mg/dL) 112.4±11.25 86.6±5.38 <0.001 
Insulin (µIU/mL) 9.04±6.53 10.26±6.87 NS 
HOMA-IR 2.24±1.58 2.35±1.45 NS 
Data are expressed as mean ± SD. P value < 0.05 are considered significant.  NS = Not significant 
Bivariate analysis for metabolic syndrome in patients with 
subclinical hypothyroidism (Table 2) shows that 33.3% of patients 
in subclinical hypothyroidism groups have hypertension. A higher 
percent of SH group had metabolic syndrome than the comparison 
group (43.3%  vs 6.66%, p=0.001). Dysglycemia is also more 
prevalent among SH group (53.3% vs 3.33%). Insulin and HOMA-IR 
did not differ between the groups. Hypertriglyceridemia was more 
prominent in SH patients.  
Table2: Bivariate analysis for metabolic syndrome in patients 














56.6% 60% X2 = 0.006 
P=0.39 




43.3% 23.3% X2 = 2.7 
P=0.1 
Triglycerides 26.6% 3.33% X2 = 6.41 
P=0.01* 
Hypertension 23.3% 3.33% X2 = 5.19 
P=0.02* 
Data are expressed as percent of subjects with abnormal results 
P value < 0.05 are considered significant.                    
Table 3 shows that a positive correlation exists between TSH levels 
and blood pressure, triglycerides and LDL-cholesterol. 
Table3: Correlation between TSH and Lipid profile and blood 
pressure 











Correlation is significant at P value < 0.05 
DISCUSSION 
In our study, we demonstrated that women with subclinical 
hypothyroidism have significantly higher prevalence of 
hypertension, hypercholesterolemia, hypertriglyceridemia and 
dysglycemia. 43.3% of SH patients are having metabolic syndrome. 
On examining each component of metabolic syndrome among these 
patients - 23.3% had hypertension, 53.3% had dysglycemia, 43.3% 
had higher waist circumference, 26.6% had high triglycerides and 
30% had decreased HDL-C levels. These findings are in concurrence 
with other studies which reported that SH would affect each 
component of metabolic syndrome including blood pressure and 
metabolism of carbohydrates and lipids [9, 10].  
The thyroid hormones are known to play a role in regulating the 
synthesis, metabolism and mobilization of lipids. A significant 
increase in total cholesterol, triglycerides and LDL-C in SH patients 
in our study is in agreement with previous research [11, 12]. No 
correlation was found between total cholesterol and thyroid 
hormone levels whereas a positive correlation exists between TSH 
and triglycerides. 26.6% of SH patients had hypertriglyceridemia. 
There is increasing evidence indicating that elevated triglyceride 
levels are independent risk factors for cardiovascular disease. 
Hypertriglyceridemia and increased C-reactive protein levels were 
documented in SH patients, suggesting low grade inflammation and 
risk factors for developing cardiovascular disease. Our findings 
concur with recent studies demonstrating that 19-30% patients with 
SH have hypertriglyceridemia [13]. 
Subclinical hypothyroid patients in the present study had higher 
levels of LDL-C which positively correlated with TSH levels. The 
increase in LDL-C levels may be accompanied by increased 
formation of oxidised LDL-C contributing to enhanced risk of 
atherosclerosis [14]. Thyroxine replacement in these patients seems 
to have a beneficial effect by decreasing cardiovascular mortality by 
9-31% [15, 16].  
Both systolic and diastolic blood pressure has been found to be 
significantly increased in subclinical hypothyroid women. TSH levels 
were found to have a positive correlation with blood pressure. In a 
large population study, a positive linear association was established 
between systolic and diastolic arterial pressure and TSH levels [17].  
Dysglycemia is more frequent among SH patients (53.3%). 
Dysglycemia has been characterized by the presence of 
cardiometabolic risk factors [18].  Insulin and HOMA-IR were not 
different between the groups. Muscle and adipose tissue are 
resistant to glucose uptake under the influence of insulin, whereas 
suppression of lipolysis by insulin is not impaired in 
hypothyroidism. Insulin resistance in muscle and adipose tissue was 
observed after stimuli but not in the fasting state. Decreased blood 
flow to these tissues might be one of the pathogenetic mechanisms 
for insulin resistance in these patients [19].  
CONCLUSION 
We have shown that subclinical hypothyroidism is significantly 
associated with metabolic syndrome and its components especially 
dysglycemia, hypertension and hypertriglyceridemia. The 
association of subclinical hypothyroidism with metabolic syndrome 
might result in a compounded cardiovascular risk which needs to be 
addressed by further studies. Therefore screening and treatment of 
metabolic syndrome may reduce the cardiovascular risk in these 
patients. 
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